Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bravida invites to a webcast with shareholders

Due to Region Skåne’s cancellation of the framework agreements with Bravida Sverige AB, Bravida invites shareholders to a webcast on April 8, at 15.00 CET.Participating in the webcast are Mattias Johansson, CEO and Group President and Åsa Neving, CFO. The webcast will be held in English and there will be an opportunity to ask questions.Join the webcast via the link below to participate and submit questions:https://ir.financialhearings.com/bravida-call-april-2024For further information, please contact: Liselotte StrayHead of Group Communicationsliselotte.stray@bravida.se+46 76

#24-124 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

#24-123 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Affilka by SOFTSWISS Announces Partnership with 10bet

Affilka by SOFTSWISS, a leading provider of affiliate tracking software for the iGaming industry, announces a new collaboration with 10bet, a prominent player in the iGaming realm.10bet operates in diverse markets, including Europe, LatAm, and Africa. Offering both casino and sportsbook solutions, 10bet brings over 20 years of global experience and expertise to the table. This partnership marks a significant milestone for both companies as they join forces to enhance affiliate marketing strategies 

Glaston Corporation: Notification of Change in Holdings according to Chapter 9, Section 10 of the Securities Markets Act

Glaston Corporation Stock Exchange Release  5.4.2024 at 17.40Glaston Corporation has on 5 April 2024 received a notification pursuant to chapter 9, section 5 of the Securities Market Act from OP-Rahastoyhtiö Oy, according to which the ownership of OP-Suomi Pienyhtiöt fund in Glaston Corporation has decreased below the threshold of 5 percent. According to the notification, the holding decreased below the threshold on 4 April 2024. The total ownership of investment funds managed by OP-Rahastoyhtiö Oy is 4.68% on 4 April 2024.  Total position of person subject to the notification obligation:

Belatra Shortlisted for Two Awards at SiGMA Americas

Belatra Games, the specialist online slots developer, has been shortlisted for Best Game Provider and Most Played Game (Mummyland Treasures) at the SiGMA Americas Awards. The prestigious awards are held on the opening night of the hugely popular LatAm iGaming networking event running across 23-25 April in Brazil, São Paulo.The SiGMA Americas Awards, celebrate the biggest triumphs in gaming, tech, and digital marketing, while also recognising inspiring individuals and companies excelling within the Americas. Belatra’s two nominations highlight the studio’s unrelenting commitment in creating

Change to the financial calendar

Company announcement no. 15 - 24Copenhagen, April 5, 2024 The release of Shape Robotics' annual report for 2023, initially scheduled for latest April 8, 2024, is anticipated to be delayed. This delay is attributed to the acquisition of Skriware, as announced in 42-23, and the associated tasks related to purchase price allocation and consolidation as per December 31[st] accordingly with IFRS standards. However, the annual report is expected to be published no later than April 12, 2024. There are no other changes in the financial calendar. The financial calendar will be updated on

Invitation to presentation of HEXPOL's Interim Report Q1 on 26 April

HEXPOL will release the Interim Report for the first quarter 2024 on Friday 26 April at about 12:00 CET. The report will be presented by HEXPOL’s acting CEO and CFO Peter Rosén at a web-casted conference call on 26 April at 13:00 CET.   The presentation can be followed on the web or over the phone.   If you wish to participate via webcast please use the link below. https://ir.financialhearings.com/hexpol-q1-report-2024   If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference

Shape Robotics calls for Annual General Meeting on 29 April 2024

Company Announcement No. 14-24Copenhagen, April 5, 2024 By reference to Section 5.5 of the Articles of Association, the Board of Directors of Shape Robotics A/S, CVR-No. 38 32 26 56, hereby gives notice of an ordinary general meeting to be held on Monday, 29 April 2024 at 13.00 (1.00 PM CET) At Bella Sky, Center Boulevard 5, DK-2300 Copenhagen S An hour before the start of the ordinary general meeting, snacks and refreshments will be served for participants attending physically. After the general meeting, there will be a short demonstration of the products and solutions that

Notice convening the annual general meeting 2024

Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, Company registration no.: DK28315694 Company announcementNo. 08/2024 Copenhagen, Denmark, April 5, 2024 (ticker: AQP) – The Board of Directors of Aquaporin A/S (“Aquaporin” or the “Company”), hereby convenes the annual general meeting of Aquaporin to be held on: Monday, April 29, 2024, at 16:00 (CEST) at the Company’s office, Nymøllevej 78, DK-2800 Kgs. Lyngby, Denmark with the following agenda Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2.

AddLife´s Annual Report for 2023 is now published

AddLife´s Annual Report for 2023 is now available online at the company website. The Annual Report can be downloaded in pdf version.Visit https://reports-en.add.life/annual-report-2023/addlife-2023/ Stockholm, April 5, 2024 AddLife AB (publ)AddLife AB, Box 3145, 103 62 StockholmTel +46 (0)8-420 038 30www.add.lifeinfo@add.life For further information, please contact:Fredrik Dalborg, VD, fredrik.dalborg@add.life, +46 70 516 09 01Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22 AddLife is an independent European player in Life Science that offers

ADDvise receives allocation decision worth EUR 1.25 million

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from the Kanta-Häme region worth EUR 1.25 million. The allocation decision pertains to the delivery of x-ray equipment to three hospitals in the region during 2024 and early 2025.   The allocation decision is subject to a customary appeals period.   For further information, please contact: Rikard Akhtarzand, CEO +46 (0) 76-525 90 71 rikard.akhtarzand@addvisegroup.se   Important information This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the

ChromoGenics AB (publ) announces allocation in directed share issue

On 5 March 2024 ChromoGenics AB (publ) ("ChromoGenics" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the extraordinary general meeting, on a directed issue of 2,505,885 shares in a total amount of SEK 16 million (the "Directed Issue"). The subscription price amounted to SEK 6.44 per share and was determined based on an accelerated bookbuilding procedure carried out by Vator Securities AB (acting as Sole Bookrunner). The subscribers in the Directed Issue consist of existing shareholders, including the Company's two largest

Scandinavian ChemoTech’s Animal Care embarks on an exciting journey along with Equitom to forge a cutting-edge Centre of Excellence

Vetiqure are expanding their partnership with Equitom, Europe's foremost equine clinic renowned for its groundbreaking advancements in equine healthcare, by establishing a Centre of Excellence for TSE.   With its distinguished reputation and status as the largest and most innovative equine clinic in Europe, Equitom has consistently pushed the boundaries of equine medicine. Vetiqure's TSE technology has been recognized by Equitom as a game-changer in the treatment of, amongst others, sarcoids, a common tumour among horses.   Following the successful integration of the vetIQure™

Inside Information: Finnish Ministry of Defence Decided on a Partnership Agreement with Bittium Wireless Ltd, a Subsidiary of Bittium Corporation

Bittium CorporationInside information Inside Information: Finnish Ministry of Defence Decided on a Partnership Agreement with Bittium Wireless Ltd, a Subsidiary of Bittium Corporation Bittium Corporation, Stock Exchange Release, April 5, 2024, at 4.00 pm (CEST+1) The Finnish Minister of Defence, Mr. Antti Häkkänen has authorized the Finnish Defence Forces to sign a partnership agreement with Bittium Wireless Ltd, a subsidiary of Bittium Corporation, for the years 2025–2036. The aim is to sign the agreement during the year 2024. The basis for the partnership is the maintaining

Diagonal Bio announces successful pilot study results and extended partnership with Hørsholm Veterinary Clinic

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces the extension of its partnership with Hørsholm Veterinary Clinic following the successful completion of a three-month pilot study. The pilot study was focused on utilizing Diagonal Bio’s platform technology, LAMPlify®, for the detection of viral infections in horses. The successful results were validated by an independent external laboratory in Germany, underscoring the efficacy and reliability of the LAMPlify® analysis system.The pilot study tested Diagonal Bio’s LAMPlify® technology on a series of samples from horses

Read original

Giant BidCo publishes a supplement to the offer document and announces that regulatory approvals have been received for the recommended public cash offer to the shareholders of Byggfakta

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE

Kamux Corporation: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act

Kamux Corporation, Stock Exchange Release / Flagging Release, 5.4.2024 at 16:00 Kamux Corporation: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act Kamux Corporation has received on April 5, 2024 the following notification pursuant to Chapter 9, Section 5 of the Securities Markets Act (“SMA”), according to which the total holding of funds (Finnish Fund) managed by Danske Bank A/S (Copenhagen, Denmark) in Kamux Corporation shares and votes has decreased below five (5) percent on April 4, 2024. According to the notification, the reason for the

Decisions by Alma Media’s Annual General Meeting and the Board of Directors in 2024

Alma Media Corporation                 Stock Exchange Release                   5 April 2025 at 3.45 p.m. (EEST)   DECISIONS BY ALMA MEDIA’S ANNUAL GENERAL MEETING AND THE BOARD OF DIRECTORS IN 2024  Alma Media Corporation’s Annual General Meeting (AGM) held today, 5 April 2023 confirmed the financial statements for 2023 and released the members of the Board of Directors and the President and CEO from liability. The AGM decided that a dividend of EUR 0.45 per share shall be paid for the financial year 2023.   Eero Broman, Heikki Herlin, Peter Immonen, Ari Kaperi, Esa Lager,

SciBase resolves on a directed issued of approximately SEK 33 million and a rights issue of approximately SEK 15 million

The Board of Directors SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved on a capital raise totaling approximately SEK 48 million (the "Capital Raising"). The Capital Raising consists of both a new issue of so called units, consisting of shares and warrants of series TO 2, with deviation from the existing shareholders' preferential rights, of approximately SEK 33 million to Ribbskottet AB, Per Olof Ejendal AB, Kåre Gilstring, Robert Molander, MLJK Konsult AB, Klintemar Konsult AB, Jesper Hoiland, Fredrik Mattsson, Stefan Hansson, Ulti AB , Van Herk Investments B.V.,

Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN DIAMYD MEDICAL AB IN ANY JURISDICTION. PLEASE REFER TO THE “IMPORTANT INFORMATION” SECTION BELOW.Diamyd Medical announces that its main shareholder

Notice of Annual General Meeting (AGM) of Bioretec Ltd

Bioretec Ltd                         Company announcement    5 April 2024 at 3:00 p.m. EETThe shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 26 April 2024 at 10:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland.   A shareholder may participate in the Annual General Meeting and exercise their rights at the meeting by way of proxy representation. A proxy representative shall present a dated power of attorney or, in another reliable manner, demonstrate their

ANNUAL GENERAL MEETING OF ORDERYOYO A/S

Company Announcement No.  71 - 2024 OrderYOYO A/S    Copenhagen, April 5, 2024 According to article 7.2 of the articles of association, an annual general meeting of OrderYOYO A/S is hereby called to be convened on Monday, April 22, 2024, at 10.00 a.m. CEST The general meeting will be held at the company's address Vesterbrogade 149DK-1620 Copenhagen VDenmark AGENDA In accordance with article 8.1 of the company's articles of association, the board of directors has prepared the following agenda: 1. Election of chairman of the meeting. 2. The board of

There are no items matching the current filter
There are no more items matching the current filter
Back to top